RecruitingNot ApplicableNCT07060378
A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes
Sponsor
Shanghai Chest Hospital
Enrollment
250 participants
Start Date
Jul 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria4
- Age \>18 years old；
- Enlargement of at least one intrathoracic LN (short diameter \> 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET / CT (standardized uptake value \> 2.5)；
- CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA;
- Patients who have good compliance and sign informed consent.
Exclusion Criteria7
- Patients with known hypersensitivity to ultrasound contrast components;
- Patients with severe pulmonary hypertension (pulmonary artery pressure \> 90 mmHg);
- Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting;
- Patients with uncontrolled essential hypertension and adults with respiratory distress syndrome;
- Pregnant or lactating women；
- Patients with contraindications to bronchoscopy；
- Patients with other conditions that, in the opinion of the investigator, make the patient unsuitable for the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEContrast-enhanced endobronchial ultrasound
Using CE-EBUS to observe pulmonary lesions and abnormal enlarged intrathoracic lymph nodes, the enhancement characteristics of benign and malignant lesions under CE-EBUS were extracted for both conditions.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07060378